Odimma Therapeutics

Odimma Therapeutics is a French biotechnology company with a unique approach in active personalized cancer immunotherapy. Odimma Therapeutics believes in the future of precision medicine and leverages the latest advancements in immuno-oncology to combat the most difficult-to-treat cancers. By harnessing the patient's own immune system’s ability to specifically recognize non-self targets (also known as neoantigens) displayed by tumors, Odimma Therapeutics has designed a powerful next-generation personalized immune platform. This proprietary platform has demonstrated its ability to induce robust cellular immune responses against non-self antigens as well as significant anti-tumor effects in tumor-bearing mice.